(Q77843547)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

title

FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference

1 reference

A J McCarthy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

L A Pitcher

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

I M Hann

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

A Oakhill

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

publication date

1 June 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

published in

Pediatric Blood & Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

page(s)

411-415

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia

8 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

The expanding role of fludarabine in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

A second course of treatment for childhood acute lymphoblastic leukaemia: long-term follow-up is needed to assess results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Treatment of relapsing acute lymphoblastic leukemia in childhood. III. Experiences with 54 first bone marrow, nine isolated testicular, and eight isolated central nervous system relapses observed 1985-1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291096-911X%28199906%2932%3A6%3C411%3A%3AAID-MPO3%3E3.0.CO%3B2-K

10.1002/(SICI)1096-911X(199906)32:6<411::AID-MPO3>3.0.CO;2-K

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10358698%20AND%20SRC:MED&resulttype=core&format=json

8 December 2019

1 reference